

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



愛 帝 宮 母 嬰 健 康 股 份 有 限 公 司
AIDIGONG MATERNAL & CHILD HEALTH LIMITED

(Incorporated in Bermuda with limited liability)

(Stock code: 286)

**(1) APPOINTMENT OF NON-EXECUTIVE DIRECTOR;
AND
(2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE
DIRECTOR**

The Board announces that, with effect from 27 December 2022:

- Ms. Liang Linmin has been appointed as non-executive Director; and
- Mr. Wang Qingyu has been appointed as an independent non-executive Director.

This announcement is made by Aidigong Maternal & Child Health Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) in accordance with Rule 13.51(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company announces that Ms. Liang Linmin (“**Ms. Liang**”) has been appointed as a non-executive Director with effect from 27 December 2022.

The biographical details of Ms. Liang are as follows:

Ms. Liang, aged 50, founder of an ophthalmology hospital. She has been working in the interior design industry for many years. Ms. Liang also has extensive experience in business management in the medical sector.

To the best knowledge of the Board and save as disclosed above, as at the date of this announcement, Ms. Liang (i) does not have any relationship with any Director, senior management, substantial Shareholder or controlling Shareholder of the Company; (ii) did not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not have any interests in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Securities and Futures Ordinance**”); (iv) does not hold any other positions with the Company or other members of the Group; and (v) does not have other major appointment or professional qualification.

Ms. Liang has entered into a service contract with the Company for an initial term of one year commencing on 27 December 2022, which shall continue thereafter subject to retirement by rotation and re-election at the annual general meeting of the Company pursuant to the bye-laws of the Company (the “**Bye-laws**”), unless and until terminated by either Ms. Liang or the Company giving to the other party not less than one month’s notice in writing. Ms. Liang shall hold office until the next following annual general meeting of the Company and be eligible for re-election in accordance with the Bye-laws. According to the terms of appointment, Ms. Liang is not entitled to any director’s fee pursuant to her service contract and is not entitled to any other emoluments for holding office as a non-executive Director.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board announces that Mr. Wang Qingyu (“**Mr. Wang**”) has been appointed as an independent non-executive Director with effect from 27 December 2022.

The biographical details of Mr. Wang are as follows:

Mr. Wang, aged 44, has been working in the pharmaceutical industry for over 10 years. He has extensive experience in marketing and business management. Mr. Wang is a member of the Dongguan Political Consultative Congress, deputy leader of the Dongguan Volunteer Expansion Service Team and vice president of the Dongguan Positive Psychology Association. Mr. Wang was selected for the “List of Chinese Good Fellows” and received awards including Outstanding Volunteer of the Chinese Volunteer Service Exchange and Gold Award of the Guangdong Volunteer Service.

To the best knowledge of the Board and save as disclosed above, as at the date of this announcement, Mr. Wang (i) does not have any relationship with any Director, senior management, substantial Shareholder or controlling Shareholder of the Company; (ii) did not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not have any interests in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance; (iv) does not hold any other positions with the Company or other members of the Group; and (v) does not have other major appointment or professional qualification.

Mr. Wang has entered into a letter of appointment with the Company for an initial term of one year commencing on 27 December 2022, which shall continue thereafter subject to retirement by rotation and re-election at the annual general meeting of the Company pursuant to the Bye-laws, unless and until terminated by either Mr. Wang or the Company giving to the other party not less than one month's notice in writing. Mr. Wang shall hold office until the next following annual general meeting of the Company and be eligible for re-election in accordance with the Bye-laws. According to the terms of appointment, an annual director's fee of HK\$100,000 will be payable to Mr. Wang and is subject to review by the Board and the remuneration committee of the Board from time to time. The remuneration was determined by the Board with reference to his duties and responsibilities as well as his qualifications, experience and the prevailing market conditions.

Mr. Wang confirmed that he has met the independence criteria as set out in Rule 3.13 of the Listing Rules.

To the best knowledge of the Board and save as disclosed above, there are no other matters and information in relation to the appointment of Ms. Liang and Mr. Wang that need to be brought to the attention of the Shareholders or the Stock Exchange nor any information that need to be disclosed by the Company pursuant to Rules 13.51(2) (h) to (v) of the Listing Rules.

The Board welcomes Ms. Liang and Mr. Wang for joining the Board.

By Order of the Board
Aidigong Maternal & Child Health Limited
Zhu Yufei
Chairman

Hong Kong, 27 December 2022

As at the date of this announcement, the Board comprises Ms. Zhu Yufei, Mr. Cheung Wai Kuen, Mr. Lin Jiang, Mr. Li Runping and Ms. Meng Lijia as executive Directors; Mr. Guo Qifei and Ms Liang Linmin as non-executive Directors; and Ms. Yu Lin, Mr. Wong Yiu Kit, Ernest, Mr. Huang Wenhua and Mr. Wang Qingyu as independent non-executive Directors.